Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Operating Leases (2018 - 2025)

Historic Operating Leases for Autolus Therapeutics (AUTL) over the last 7 years, with Q3 2025 value amounting to $65.8 million.

  • Autolus Therapeutics' Operating Leases rose 2605.07% to $65.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.8 million, marking a year-over-year increase of 2605.07%. This contributed to the annual value of $49.6 million for FY2024, which is 629.83% down from last year.
  • According to the latest figures from Q3 2025, Autolus Therapeutics' Operating Leases is $65.8 million, which was up 2605.07% from $64.5 million recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Operating Leases peaked at $65.8 million during Q3 2025, and registered a low of -$1.1 million during Q3 2021.
  • Its 5-year average for Operating Leases is $33.8 million, with a median of $44.7 million in 2023.
  • Per our database at Business Quant, Autolus Therapeutics' Operating Leases crashed by 10224.85% in 2021 and then skyrocketed by 2144428.57% in 2022.
  • Autolus Therapeutics' Operating Leases (Quarter) stood at $21.0 million in 2021, then increased by 15.52% to $24.3 million in 2022, then soared by 118.37% to $53.0 million in 2023, then decreased by 6.3% to $49.6 million in 2024, then surged by 32.65% to $65.8 million in 2025.
  • Its Operating Leases stands at $65.8 million for Q3 2025, versus $64.5 million for Q2 2025 and $57.7 million for Q1 2025.